Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2023-10-27 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力关于公司2023年前三季度主要经营数据的公告
Interim / Quarterly Report Classification · 90% confidence The document is titled as an announcement regarding the company's main operating data for the first three quarters of 2023. It contains detailed financial data such as revenue, cost, and gross margin segmented by industry, treatment field, product, and region for the period January to September 2023. The document explicitly states that the data is unaudited and is a disclosure of main operating data rather than a full financial report. The length is about 3,076 characters, which is relatively short and typical for a quarterly operating data announcement rather than a comprehensive interim report. There is no indication that this is a full interim or quarterly report with comprehensive financial statements and analysis, nor is it an earnings release with key highlights only. It is a detailed operating data announcement for the first three quarters, which fits best under the category of Interim / Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. Therefore, the classification is IR with high confidence. 9M 2023
2023-10-27 Chinese
天士力关于控股子公司获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its subsidiary receiving approval from the National Medical Products Administration (国家药品监督管理局) for a clinical trial of a drug. It details the drug's name, indications, regulatory approval, and related R&D information. The document is relatively short (1796 characters) and focuses on regulatory approval news rather than presenting financial data or detailed reports. It does not contain financial statements, management discussion, or detailed financial results. It is an official announcement about a regulatory milestone related to drug development. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-09-27 Chinese
天士力对外投资管理制度（2023年9月修订）
Governance Information Classification · 95% confidence The document is titled '对外投资管理制度' (External Investment Management System) and is a detailed internal policy document outlining the company's procedures, approvals, organizational responsibilities, financial management, and disclosure requirements related to external investments. It references relevant laws and regulations but does not contain financial statements, earnings data, or audit opinions. It is a governance and management policy document rather than a financial report, announcement, or regulatory filing. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-09-25 Chinese
天士力独立董事制度
Governance Information Classification · 95% confidence The document is a detailed internal governance policy specifically about the independent director system of a company, including their roles, responsibilities, nomination, and operational procedures. It references relevant laws and regulatory bodies such as the China Securities Regulatory Commission and Shanghai Stock Exchange rules. The content is focused on governance structure and practices rather than financial results, audit opinions, or shareholder meeting materials. It is not a report of financial performance, audit, or meeting results, nor is it a brief announcement or presentation. This document fits the definition of Governance Information (CGR), as it details the company's internal rules and governance practices regarding independent directors.
2023-09-25 Chinese
辽宁天士力大药房连锁有限公司2021年1月1日至2023年3月31日止模拟财务报表审计报告
Regulatory Filings
2023-09-25 Chinese
济南平嘉大药房有限公司2021年1月1日至2023年3月31日止财务报表审计报告
Regulatory Filings
2023-09-25 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.